How long does it typically take for withdrawal symptoms to improve after discontinuing sertraline?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sertraline Withdrawal Symptoms: Timeline for Improvement

Withdrawal symptoms from sertraline discontinuation typically resolve spontaneously within 1-3 weeks after onset, with most symptoms improving within approximately 2 weeks. 1, 2

Symptom Onset and Duration

When symptoms begin:

  • Discontinuation symptoms typically commence within 1 week of stopping sertraline 1
  • Symptoms can emerge following missed doses or acute discontinuation 3

How long symptoms last:

  • Most symptoms are mild and resolve spontaneously within 3 weeks 1
  • The average duration is approximately 11.8 days (range up to 21 days) 4
  • Symptoms typically last 1-2 weeks in most patients 2

Characteristic Symptoms

The discontinuation syndrome presents with diverse physical and psychological symptoms 1:

  • Most common: dizziness, nausea, lethargy, and headache 1
  • Additional symptoms: fatigue, insomnia, imbalance, vertigo, sensory disturbances, paresthesias, anxiety, irritability, agitation, myalgias, chills, vomiting, and diarrhea 3

Rapid Resolution with Reinstatement

If symptoms are intolerable, restarting sertraline leads to resolution within 24-48 hours 1, 4. This rapid response confirms the diagnosis and can guide management decisions 4.

Risk Factors and Clinical Context

Sertraline has been specifically associated with discontinuation syndrome, though to a lesser extent than paroxetine 3. The syndrome is more likely with:

  • Longer duration of treatment (median 28 weeks in cases versus 16 weeks in non-cases) 4
  • Abrupt discontinuation rather than gradual tapering 2
  • Treatment for at least 6 weeks 2

Prevention Strategy

To minimize withdrawal symptoms, sertraline should be tapered gradually rather than stopped abruptly 5, 6. The FDA label specifically recommends: "A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate." 6

Monitoring Recommendations

Patients should be monitored for withdrawal symptoms for at least 2 weeks after discontinuation 6. Close follow-up is particularly important during the first 8-12 weeks after stopping, as this represents the highest risk period for symptom emergence 7.

Important Clinical Pitfall

The discontinuation syndrome can be misdiagnosed as relapse of the underlying condition or emergence of a new psychiatric disorder 2. The key distinguishing features are:

  • Temporal relationship: symptoms begin within days of discontinuation 1
  • Rapid response to reinstatement: resolution within 24-48 hours of restarting medication 1, 4
  • Characteristic symptom cluster: predominantly somatic symptoms (dizziness, nausea, sensory disturbances) rather than pure mood symptoms 8

References

Research

The SSRI discontinuation syndrome.

Journal of psychopharmacology (Oxford, England), 1998

Research

Antidepressant discontinuation syndrome.

American family physician, 2006

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Serotonin reuptake inhibitor withdrawal.

Journal of clinical psychopharmacology, 1996

Guideline

practice parameter on the use of psychotropic medication in children and adolescents.

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.